



Resource impact statement

Resource impact

Published: 13 May 2020

www.nice.org.uk

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact to routine commissioning of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).

This is because the population size is small (around 60 people commencing treatment per year). Additionally, the treatment is already in use in the Cancer Drugs Fund and there is not anticipated to be a significant increase in the number of patients commencing treatment when it moves into routine commissioning.

The company has a commercial arrangement (simple discount patient access scheme). This makes obinutuzumab with bendamustine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.